Stevanato Group reported Q2 2026 revenue of €302 million, an 8% increase year-over-year, driven by a 9% rise in the Biopharmaceutical and Diagnostic Solutions segment. High-value solutions (HVS) grew 16% to €136 million, representing 45% of total revenue. Adjusted EBITDA increased 21% to €78.7 million with an adjusted operating profit margin expansion to 18.0%. The company divested its California-based subsidiary Balda C. Brewer, recording a one-time loss of €12.2 million. Stevanato updated its full-year 2026 guidance, lowering the revenue midpoint slightly but maintaining organic growth expectations of 8% to 10% and adjusted diluted EPS of €0.60 to €0.62. The company operates in the pharmaceutical packaging and drug delivery systems industry.
